| Code | CSB-RA011590MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to tralokinumab, specifically targeting interleukin-13 (IL-13), a key type 2 cytokine involved in allergic and inflammatory responses. IL-13 plays a central role in the pathogenesis of various allergic diseases by promoting IgE synthesis, mucus hypersecretion, airway hyperresponsiveness, and fibrosis. This cytokine is critically implicated in atopic dermatitis, asthma, idiopathic pulmonary fibrosis, and eosinophilic esophagitis, where it drives inflammatory cascades and tissue remodeling processes.
Tralokinumab is a human IgG4 monoclonal antibody that specifically binds to IL-13, preventing its interaction with IL-13 receptor complexes and thereby neutralizing its biological activity. This biosimilar antibody serves as a valuable research tool for investigating IL-13-mediated signaling pathways, exploring type 2 inflammation mechanisms, and studying therapeutic interventions in allergic and fibrotic diseases. It enables researchers to examine cytokine blockade strategies and evaluate IL-13's role in disease models and translational studies.
There are currently no reviews for this product.